Science Market Update
(Image courtesy of Wikimedia commons)
University of Alabama at Birmingham received a $29 million grant from the National Cancer Institute. This five year core grant will support six research programs at the UAB Comprehensive Cancer Center. The renewal of the Cancer Center Support Grant, the most prestigious federal grant that a cancer research and treatment program can earn, also extends UAB’s elite “comprehensive” designation. According to the UAB News website this designation is awarded for scientific excellence and the ability to integrate diverse research approaches in the fight against cancer.Read More
Tags: Bioresearch funding, cancer research, Alabama, University of Alabama, Cancer Treatment, Cancer, University of Alabama Birmingham, UAlab, UAB, University of Alabama at Birmingham, Cancer Center, cancer researchers, fight cancer, 2016, cancer reserach, Bioresearch Grant, Comprehensive Cancer Center
(Photo courtesy of of wikimedia commons)
With Zika outbreaks in Mexico, Central America, and South America, the National Institute of Child Health and Human Development (NICHD) is attempting to stop the virus at our border. To assist with this effort, the institute is funding a study led by Dr. William Britt, Professor of Pediatric Infectious Diseases at the University of Alabama at Birmingham (UAB). This study will take place in Brazil, where the World Health Organization (WHO) estimates that between 500,000 and 1.5 million people have been infected by Zika. The study will follow pregnant women in Brazil regardless of their Zika virus infection status and follow the infants suspected of having Zika from birth until 2 years of age.Read More
The University of Alabama is an unexpected standout in the science research marketplace. This campus ranks among the top in the nation, flanking closely with the top NIH funded universities, and yet there is surprisingly little sales rep traffic on campus.
The University of Alabama at Birmingham has been awarded a $7 million research grant to continue its leadership in pioneering clinical trials in the treatment of neurofibromatosis 1 and 2 and schwannomatosis, all rare genetic diseases. According to the Birmingham Business Journal, the circumstances of these diseases lead to non-cancerous tumors forming on the nerves and potentially causing blindness, hearing loss, learning disabilities, pain or deformity.